Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Der Schlüssel zum Erfolg: Könnte sich hier eine 1.000?%-Chance verbergen!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40J1L | ISIN: CA22112H1010 | Ticker-Symbol: ET8
Tradegate
14.05.25 | 20:43
2,860 Euro
-5,92 % -0,180
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
COSCIENS BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
COSCIENS BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,0203,12006:53

Aktuelle News zur COSCIENS BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCOSCIENS Biopharma GAAP EPS of -$1.16, revenue of $1.5M4
DiCOSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update51Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures...
► Artikel lesen
DiCOSCIENS Biopharma Inc. - 6-K, Report of foreign issuer1
02.05.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer3
14.04.Cosciens Biopharma Inc: Cosciens Biopharma appoints Biehn as CEO4
14.04.COSCIENS Biopharma ernennt Anna Biehn zur neuen CEO4
14.04.COSCIENS Biopharma names Anna Biehn as new CEO1
14.04.COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer17825+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO...
► Artikel lesen
COSCIENS BIOPHARMA Aktie jetzt für 0€ handeln
09.04.COSCIENS Biopharma Inc. - 20-F, Annual and transition report of foreign private issuers3
09.04.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer2
09.04.COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update163Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Ongoing streamlined efficiencies and cost cutting measures taken to refine operations...
► Artikel lesen
02.04.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer4
02.04.Cosciens Biopharma Inc: Cosciens receives management cease trade order2
02.04.COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order7
21.03.Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday?6
20.03.COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents424Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified...
► Artikel lesen
20.03.Cosciens Biopharma Inc: Cosciens Biopharma may delay filing 2024 financials3
13.03.Cosciens Biopharma Inc: Cosciens starts phase 2a study on avenanthramides5
13.03.COSCIENS Biopharma Advances Avenanthramide Clinical Trial To Phase 2a For Inflammation Treatment5
13.03.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer1
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,14